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Cushing syndrome is rare in infancy and usually due to an adrenocortical tumor (ACT). We report an infant with Cushing
syndrome due to adrenocortical carcinoma. The patient presented at six months of age with a three-month history of growth
failure, rapid weight gain, acne, and irritability. Physical examination showed obesity, hypertension, and Cushingoid features.
Biochemical evaluation showed very high serum cortisol, mildly elevated testosterone, and suppressed ACTH. Abdominal MRI
revealed a heterogeneous right adrenal mass extending into the inferior vena cava. Evaluation for metastases was negative. The
tumor was removed surgically en bloc. Pathologic examination demonstrated low mitotic rate, but capsular and vascular invasion.
She received no adjuvant therapy. Her linear growth has improved and Cushingoid features resolved. Hormonal markers and
quarterly PET scans have been negative for recurrence 24 months postoperatively. In conclusion, adrenocortical neoplasms in
children are rare, but should be considered in the diﬀerential diagnosis of Cushing syndrome.
Copyright © 2009 Elizabeth B. Fudge et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Adrenocortical carcinoma is a rare malignancy comprising
only about 0.2% of all cases of childhood cancer. This rare
malignancy is associated with a high rate of recurrence
and mortality with a reported 5-year event-free survival
estimate of 54.2% in children. Pediatric adrenocortical
tumors (ACTs) occur most commonly in females and in
children less than four years [1]. Eighty to ninety per-
cent of patients have functional tumors with endocrine
manifestations at diagnosis and the majority present with
virilization, alone or in combination with overproduction
of other adrenal hormones. Isolated Cushing syndrome is
rare [1, 2]. We report an infant with Cushing syndrome
without the clinical features of androgen or mineralocor-
ticoid excess, consequently diagnosed with adrenocortical
carcinoma.
2. Case Report
The patient is a Caucasian female born at term with
a birth weight of 3.06 kg; pregnancy and delivery were
uncomplicated. At six months of age, she was referred
to pediatric endocrine clinic due to features of Cushing
syndrome. She had a three month history of progressive
Cushingoid facies, acne and irritability. Her linear growth
apparently had been arrested between three and six months
of age, although she gained weight at an accelerated rate
(Figure 1). Prior to referral, laboratory evaluation by her
primary care physician revealed serum cortisol of 240mcg/dl
(normal, 4.5–22.7mcg/dl); total testosterone of 185 ng/dl
(normal, 6–77ng/dl), and DHEA-S of 401mcg/dl (normal,
16–96mcg/dl). Serum ACTH was less than 5 pg/ml (normal,
10–60 pg/ml).
Her weight at initial evaluation in our clinic at six
months of age was 7.52 kg (60–75th percentile) and
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Figure 1: Growth chart demonstrating impairment of linear
growth, a classic feature of Cushing Syndrome, prior to diagnosis.
After surgical removal of tumor, the patient exhibited catch-up
growth during the following six months.
Figure 2: Physical examination of the patient revealed features of
Cushing Syndrome including round facies, acne, plethora, central
obesity, and poor muscle tone; she lacked clitoromegaly, hirsutism
or other signs of virilization.
length was 59.1 cm (<5th percentile). Blood pressure was
110/70mmHg. Physical examination showed Cushingoid
facies, buﬀalo hump, facial acne, and poor muscle tone
(Figure 2). There were no signs of virilization. Family history
was noncontributory.
An MRI of the abdomen showed a heterogeneous right
adrenal mass measuring 3.6 × 5.4 × 3.8 cm; this mass was
found to extend as a tumor thrombus into the inferior
vena cava. The tumor thrombus appeared to extend to
approximately 2 cm from the right atrium. There were no
metastases seen in the liver or lungs on MRI. A Doppler
ultrasound showed minimal, but present flow around the
IVC tumor thrombus which measured 2.5 × 0.9 × 1 cm.
Laboratory evaluation showed serum cortisol 70.8mcg/dl
(normal, 4.5–22.7mcg/dl); aldosterone 4.2 ng/dl (normal
6.5–86.0 ng/dl); testosterone 59 ng/dl (normal, 6–77 ng/dl);
ACTH < 5 (normal, 10–60 pg/ml).
The patient underwent surgical resection of the mass
ten days after diagnosis. She was prescribed ketoconozole
prior to surgery due to moderately elevated blood pressure.
However, this was not well tolerated by the patient and was
discontinued.
Surgical resection was undertaken and intraoperative
findings showed a large, well-circumscribed mass in the right
adrenal gland measuring 5.2 × 4.0 × 3.5 cm mass which did
not invade the liver, kidney or other surrounding soft tissues.
On intraoperative transesophageal echocardiography, there
appeared to be thickening of the wall of the superior vena
cava of unknown significance. The intracaval clot did not
extend to the right atrium and cardiopulmonary bypass
was not required. Blood flow was visualized around the
caval clot with no evidence of adherence to the caval wall.
The adrenal mass and thrombus were removed en bloc
(Figure 3(a)).
Pathologic examination revealed a 43 gram mass which
demonstrated capsular and vascular invasion. The mass
showed five to ten percent necrosis of the mass with spotty
calcifications (Figures 3(b) and 3(c)). The surgical margins
were negative. She received stress dosing with hydrocortisone
during and after surgery; she was reduced to a physiologic
replacement dose by 15 days postoperatively.
She was considered to have Stage 1 adrenocortical
carcinoma based on the relatively small tumor size, complete
surgical resection, lack of metastases, and normalization
of hormonal markers postoperatively. The tumor cells
demonstrated a low mitotic count (<1 to 2 per 50 high
power fields and no atypical mitoses). In addition, the MIB-
1 index was low at <1% to 12% with regional variability.
Tumor immunohistochemistry for p53 protein showed weak
staining with no accumulation in the nucleus; when p53
amplification is present, the defective proteins accumulate
within the nucleus due to abnormal cellular processing. To
evaluate for a germline p53 mutation in the patient, whole
gene sequencing was performed for the TP53 gene and did
not reveal any known mutation. No adjunctive therapies
were recommended. Quarterly PET scanning to monitor for
recurrence is underway, and has been negative for 24 months
post-operatively.
Adrenal markers were measured after surgery and at
monthly intervals. Two months after surgery, laboratory
evaluation showed total testosterone level of <7.0 ng/dl (nor-
mal, 6–77 ng/dl); DHEA <1.0ng/ml (normal, <2.9 ng/ml);
DHEA-S <15.0 ng/dl (normal, 16–96mcg/dl). ACTH was
7.6 pg/ml (normal, 10–60 pg/ml). Hormonal markers remain
normal up until time of publication. Growth velocity began
to increase within two months after surgery, and five
months after surgery was 25 cm/year consistent with catch-
up growth.
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Figure 3: (a) Grossly, the resected specimen showed a well-circumscribed tumor without normal adrenal gland. The tumor measured
5.2×4×3.5 cm and weighed 43 gm. (b) Adrenal cortical carcinoma with necrosis (upper field) and coarse calcifications. (c) Adrenal cortical
carcinoma. Richly vascular neoplasm composed of nodules of tumor cells with lightly eosinophilic cytoplasm. The tumor contains bands of
fibrous tissue and coarse calcifications (Hematoxylin and eosin, 20X).
3. Discussion
Our patient demonstrated classic features of glucocorticoid
excess including growth failure, hypertension, acne, plethora
and a buﬀalo hump with excessive weight gain. She had bio-
chemical evidence for excessive glucocorticoid production.
The diﬀerential diagnosis of Cushing syndrome in an infant
includes adrenocortical tumors (carcinoma or adenomas),
as well as multinodular adrenal hyperplasia. In addition,
Cushing disease, ectopic ACTH production, and iatrogenic
Cushing syndrome should be considered. Miller et al.,
demonstrated that of 60 infants with Cushing syndrome, 48
had adrenal tumors. Two had ectopic ACTH production, five
had nodular adrenal hyperplasia, four had undefined adrenal
hyperplasia and one had an ACTH producing tumor [3].
Therefore, first an adrenocortical tumor should be excluded
in an infant with Cushing syndrome as long as there is no
history for exposure to exogenous glucocorticoids. In our
case, suppressed ACTH level was consistent with a peripheral
source. The unilateral adrenal mass in the MRI indicated an
adrenal tumor and histopathological findings confirmed an
adrenocortical carcinoma.
Pediatric adrenocortical tumors have distinct clinical and
biological features in comparison to those which occur in
adults. It is estimated that there are 19–20 new cases of
adrenocortical carcinoma in children and adolescents per
year in the United States according to the Surveillance,
Epidemiology and End Results Program. Most of these
patients are either toddlers, early school age children or
in their late teens as pediatric adrenocortical tumors have
a bimodal age distribution. There is a peak in incidence
before four years of age (0.4 cases per million) which then
declines during the subsequent ten years. The incidence then
rises to 0.2 per million during the late teens. Interestingly,
the majority (60%) of pediatric adrenocortical tumors
occur in children less than five years which is similar to
the distribution seen with tumors of embryonic origin
[1].
Although our patient fits the common age distribution
for an adrenocortical tumor, her presentation with Cushin-
goid features alone is unusual especially at such a young
age. Although biochemically she demonstrated elevations
in both androgens and cortisol, she had no evidence of
virilization on physical examination. Michalkiewicz et al.,
found in a registry of 254 pediatric patients with ACTs
that 55% presented with virilization alone. Twenty-nine
percent presented with mixed overproduction of adrenal
hormones. Only 5.5% percent of this group presented with
isolated Cushing syndrome, and this tended to occur in older
children (median age, 12.6 years). In addition, Lefevre et
al., showed similar results in their analysis of 42 children
with ACTs in France. More than 90% of patients presented
with virilization. Therefore, our patient is remarkable in that
she presented with Cushingoid features alone during infancy
[1].
The tendency for adrenocortical tumors to occur in
younger age groups and to be predominantly androgen-
producing could be linked to their relationship to the
fetal adrenal cortex. The fetal adrenal cortex is composed
of two distinct zones: the outer definitive zone which
is steroidogenically quiescent until late gestation and an
inner zone which appears to produce steroid hormones
throughout gestation. The inner fetal zonemakes up 85–90%
of the total fetal adrenal cortex at birth from which time it
begins to undergo apoptosis. The histopathologic features of
ACTs in young children suggest that they arise from the fetal
zone which has a tendency towards androgen production
due to diﬀerential expression of steroidogenic enzymes at
diﬀerent times in development. The primary steroid product
of the fetal adrenal cortex is dehydroepiandrosterone sulfate
(DHEA-S) which is the precursor of placental estrogen [4].
Thus, the derivation of adrenocortical tumors of infants,
and young children from the fetal zone of the adrenal
cortex could help to explain their preferential elaboration of
androgens.
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Our patient’s tumor was negative for p53 mutation
which is estimated to occur in 80–90% of all pediatric
adrenocortical tumors. Interestingly, a distinct germline p53
mutation, TP53 R337H, has been described in Brazilian
patients with adrenocortical tumors [5, 6]. This mutation
leads to an abnormal folding of the TP53 protein and
accumulation in the nucleus; loss of heterozygosity at this
locus is though to be involved in tumorigenesis. In a study
evaluating penetrance of this mutation, 10% of 240 carriers
of this mutation developed adrenocortical tumors [7].
Our patient has a favorable prognosis given complete
surgical resection, small tumor size, lack of metastasis and
young age. From the International Pediatric Adrenocortical
Tumor Registry report including data from 254 patients,
those with completely resected tumors weighing less than
200 gm and without metastasis, had a five year event free
survival rate of 91%. This study also showed that age less
than four years was independently associated with better
prognosis; multivariate analysis showed adjusted odds ratio
of 2.6 for age less than four years [1]. Therefore, our patient
has an excellent prognosis. As mentioned earlier, her follow-
up PET scans and hormonal markers have remained negative
for 24 months postoperatively.
In conclusion, although rare, ACTs should be considered
in the diﬀerential diagnosis of Cushing syndrome in the
pediatric age group. While virilizing features are typically
dominant, ACTs may present with isolated Cushing syn-
drome. Early diagnosis, adequate perioperative manage-
ment with specific emphasis on postoperative glucocorticoid
replacement, complete excision of tumor and close follow-up
for recurrence andmetastases are crucial to improve survival.
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